- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Inhibrx BLA for ozekibart accepted by FDA | 1 | Seeking Alpha | ||
| 15.06. | FDA akzeptiert Zulassungsantrag von Inhibrx für Medikament gegen seltenen Knochenkrebs | 3 | Investing.com Deutsch | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.06. | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | 253 | PR Newswire | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| 03.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | Stifel reiterates Inhibrx Biosciences stock rating on durability data | 1 | Investing.com | ||
| 02.06. | Inhibrx: Stifel bestätigt Kaufempfehlung nach überzeugenden Daten zur Wirkungsdauer | 2 | Investing.com Deutsch | ||
| 14.05. | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | 540 | PR Newswire | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| 11.05. | Inhibrx delivers 'differentiated' cancer drug data; Fractyl starts diabetes gene therapy trial | 4 | BioPharma Dive | ||
| 11.05. | Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data | 5 | FierceBiotech | ||
| 11.05. | Inhibrx reports interim phase 2 data for cancer drug trial | 2 | Investing.com | ||
| 11.05. | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | 354 | PR Newswire | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| 08.05. | Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset | 1 | Seeking Alpha | ||
| 22.04. | Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges | 1 | Benzinga.com | ||
| 22.04. | Stifel raises Inhibrx Biosciences price target on trial optimism | 2 | Investing.com | ||
| 22.04. | Stifel verdoppelt Kursziel für Inhibrx Biosciences aufgrund von Studienoptimismus | 2 | Investing.com Deutsch | ||
| 22.04. | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | 995 | AFX News | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 22.04. | Inhibrx cancer drug reportedly drawing interest of Merck and rivals | 3 | Seeking Alpha | ||
| 21.04. | Inhibrx meldet 20 % Ansprechrate für Ozekibart in Darmkrebs-Studie | 3 | Investing.com Deutsch | ||
| 21.04. | Inhibrx reports 20% response rate for ozekibart in CRC trial | 1 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VIRAX BIOLABS GROUP | 6,340 | +99,37 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,470 | +1,25 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,57 | +0,24 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| ABSCI | 11,465 | +3,29 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,15 | -5,29 % | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | ||
| BEAM THERAPEUTICS | 35,840 | -2,82 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,420 | -0,02 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 48,380 | +4,49 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| ERASCA | 19,180 | +1,64 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,765 | +1,21 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,770 | +0,95 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| ALUMIS | 30,270 | +1,78 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD | ||
| RELAY THERAPEUTICS | 20,750 | +5,71 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| CG ONCOLOGY | 73,34 | +5,07 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
INHIBRX BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 104,00 Euro und damit +7,11 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.